Form 13-F position report

AERIE PHARMACEUTICALS INC

Reported by PRICE T ROWE ASSOCIATES INC MD

AERI CUSIP 00771V108 Manager CIK 0000080255

Reported 0 shares, down 28,234 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q4 2022
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 26 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 94000
2022-03-31 105000
2022-06-30 118000
2022-09-30 428000
2022-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

5 quarters
Quarterly reported position history for AERIE PHARMACEUTICALS INC held by PRICE T ROWE ASSOCIATES INC MD.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2022 Reduced 0 -28,234 (-100.0%) 0 $0 2023-02-14
Q3 2022 Added 28,234 +12,519 (79.7%) < 0.01% $428,000 2022-11-14
Q2 2022 Added 15,715 +4,203 (36.5%) < 0.01% $118,000 2022-08-15
Q1 2022 Reduced 11,512 -1,892 (-14.1%) < 0.01% $105,000 2022-05-16
Q4 2021 Reduced 13,404 -15,700 (-53.9%) < 0.01% $94,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

153 managers reported AERIE PHARMACEUTICALS INC for Q4 2022.

Managers reporting AERIE PHARMACEUTICALS INC in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
NATIXIS ADVISORS L P Reduced 0 -37,375 0 $0 9 qtrs
GHP Investment Advisors Inc Reduced 0 -400 0 $0 2 qtrs
MARTINGALE ASSET MANAGEMENT L P Reduced 0 -38,299 0 $0 2 qtrs
Virtu Financial LLC Reduced 0 -25,101 0 $0 2 qtrs
The Goldman Sachs Group Inc Reduced 0 -939,811 0 $0 35 qtrs
DAFNA Capital Management LLC Reduced 0 -307,232 0 $0 34 qtrs
NEW YORK STATE COMMON RETIREMENT FUND Reduced 0 -61,094 0 $0 31 qtrs
Qube Research & Technologies Ltd Reduced 0 -221,266 0 $0 2 qtrs
SCHRODER INVESTMENT MANAGEMENT GROUP Reduced 0 -1,500,183 0 $0 13 qtrs
PenderFund Capital Management Ltd Reduced 0 -22,950 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
COMM STK

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.